# Single GPU Task Adaptation of Pathology Foundation Models for Whole Slide Image Analysis

# Neeraj Kumar

Memorial Sloan Kettering Cancer Center kumarn6@mskcc.org

#### **Chad Vanderbilt**

Memorial Sloan Kettering Cancer Center vanderbc@mskcc.org

## **Abstract**

Pathology foundation models (PFMs) have emerged as powerful tools for analyzing whole slide images (WSIs). However, adapting these pretrained PFMs for specific clinical tasks presents considerable challenges, primarily due to the availability of only weak (WSI-level) labels for gigapixel images, necessitating multiple instance learning (MIL) paradigm for effective WSI analysis. This paper proposes a novel approach for single-GPU Task Adaptation of **PFM**s (TAPFM) that uses vision transformer (ViT) attention for MIL aggregation while optimizing both for feature representations and attention weights. The proposed approach maintains separate computational graphs for MIL aggregator and the PFM to create stable training dynamics that align with downstream task objectives during end-to-end adaptation. Evaluated on mutation prediction tasks for bladder cancer and lung adenocarcinoma across institutional and The Cancer Genome Atlas (TCGA) cohorts, TAPFM consistently outperforms conventional approaches, with H-Optimus-0 (TAPFM) outperforming the benchmarks. TAPFM effectively handles multi-label classification of actionable mutations as well. Thus, TAPFM makes adaptation of powerful pre-trained PFMs practical on standard hardware for various clinical applications.

## 1 Introduction

Hematoxylin and Eosin (H&E) staining is the most common slide preparation method in pathology, used for visualizing tissue architecture and cellular details for cancer diagnosis. Whole slide images (WSIs) serve as high-resolution digital representations of these tissue slides, commonly scanned at either  $20\times$  or  $40\times$  optical resolution that captures  $0.50\mu^2$  or  $0.25\mu^2$  of tissue per pixel, respectively. WSIs form the basis of computational pathology that employs machine learning (ML) and computer vision techniques for digital cancer assessment [1]. Due to memory constraints preventing direct processing of gigapixel WSIs and the availability of only slide-level labels for clinical tasks, WSI processing adopts a multiple instance learning (MIL) approach. In the MIL framework, each WSI is represented as a bag of smaller tiles (e.g.,  $224\times224\times3$ ); a neural network encodes each tile into a feature embedding, and the tile embeddings are then aggregated into a slide-level bag representation to compute predictions using only bag-level labels during training [2, 3], as illustrated in Figure 1.

Computational pathology has experienced a paradigm shift with the introduction of pathology foundation models (PFMs), which learn powerful representations from large collections of WSIs through self-supervised pre-training of vision transformers (ViTs) [4, 5, 6, 7, 8, 9]. For specific downstream applications such as gene mutation prediction, survival analysis, and treatment response estimation, existing methods typically use these PFMs as fixed feature extractors and train separate MIL aggregators to generate slide-level predictions [2, 10]. The fixed-feature approach fails to adapt PFM parameters to the specific downstream task, potentially limiting performance [11, 12, 13]. To address this limitation, we propose a novel Task Adaptation of Pathology Foundation Models (TAPFM) approach that: (1) leverages ViT's internal attention mechanism for MIL aggregation,

(2) maintains separate computational graphs for PFM and MIL parameter updates with a dual-loss mechanism on a single GPU, and (3) seamlessly integrates with popular PFMs to improve their performance on clinically relevant tasks.




Figure 1: WSI Processing Pipeline – A representative H&E stained WSI scanned at  $40\times$  optical resolution with  $100,000\times125,000$  RGB pixels. For efficient processing, manageable sized tiles (e.g.  $224\times224\times3$ ) shown in black boxes are usually extracted from the tissue region. Bag of tiles obtained from a WSI are then passed through a pathology foundation model to obtain feature representations (one feature vector per tile) which are then combined using multiple instance learning methods to compute a bag feature vector (one per WSI) that is used for downstream tasks such as binary classification (e.g. gene mutation prediction: 0 for absence and 1 for presence of mutation).

## 2 Related Work

## 2.1 Pathology Foundation Models (PFMs)

CTransPath [14] established an early benchmark by training a hybrid convolutional-transformer architecture on 32,220 WSIs across 25 anatomic sites. HIPT [15] and REMEDIS [16] explored different architectural approaches with ViT-S (DINO [17]) and ResNet-50 (SimCLR) respectively. Phikon [18] demonstrated the efficacy of ViT-L trained with iBOT on TCGA slides, while UNI [5] significantly expanded scale with its ViT-H architecture trained via DINOv2 [19] on 100,000 slides across 20 tissue types. Subsequent models pushed boundaries further with Virchow [6] exploring a ViT-huge model trained on 1.5 million WSIs. This trend toward increased scale continued with Prov-GigaPath [8] processing 1.3 billion tiles from 171,189 WSIs spanning 31 tissue types and Virchow2 [7] scaling to 1.7 billion tiles from 3.1 million slides across multiple magnifications. H-optimus-0 [9] leveraged ViT-giant architecture trained on hundreds of millions of tiles from over 500,000 WSIs. Several approaches have explored multimodality, including vision-language models (CONCH [20], PRISM [21], MUSK [22]) and vision-genomics integration (Orpheus [23]), expanding PFMs beyond visual representation learning. Despite this architectural diversity, vision-only models including UNI [5], GigaPath [8], and H-optimus-0 [9] have demonstrated superior performance on clinically relevant tasks such as cancer diagnosis, mutation prediction, and treatment response estimation [13]. The dominant architecture across these PFMs remains ViTs [4] trained through self-supervised learning, predominantly using DINOv2 [19], on diverse WSI data. This paper specifically focuses on ViT based PFMs that utilize only pathology images as input.

# 2.2 Multiple Instance Learning (MIL) in Computational Pathology

MIL methods for WSI analysis have evolved from attention-based mechanisms to spatial-aware architectures. Early MIL approaches used simple aggregation operations such as mean or max pooling to combine tile-level features [3]. A major advance was attention-based MIL (ABMIL) [2], which learns attention weights to prioritize diagnostically relevant tiles. CLAM [10] extended attention based MIL for multi-class classification. DSMIL [24] introduced a dual-stream approach coupling max-pooling with attention scoring. VarMIL [25] incorporated variance modeling to capture tissue heterogeneity while maintaining computational efficiency. Spatially aware MIL methods have also emerged to capture relationships between WSI tiles. TransMIL [26] leveraged transformer architectures with positional encoding, while graph-based approaches like PatchGCN [15] represent tiles as nodes in a graph structure based on physical adjacency. Graph transformer processing (GTP) [27] further refined this approach by combining graph structures with attention mechanisms. Despite architectural advances, benchmarking studies reveal that performance depends heavily on

the specific clinical task and the quality of input embeddings, with no single aggregation method consistently outperforming others across all applications [28].

## 2.3 Task Adaptation of PFMs

MIL methods usually rely on PFMs as fixed feature extractors, creating a disconnect between representation learning and task-specific adaptation for WSI analysis. Li et al. [29] proposed an Information Bottleneck (IB) based fine-tuning approach that addresses computational constraints through instance sparsification on smaller backbone models (ResNet-50). The multiple forward passes required by the IB approach make it computationally infeasible for modern large-scale PFMs on single GPU systems due to memory constraints. While recent approaches have attempted to avoid multiple forward passes through end-to-end fine-tuning of large-scale PFMs [30, 31], these methods typically require substantial computational resources spanning tens of GPUs. Most recently, Campanella et al. [32] demonstrated the clinical utility of PFM adaptation for *EGFR* mutation prediction in Lung cancer patients, but required distributed training across 24 NVIDIA H100 GPUs. Such computational requirements place PFM adaptation beyond the reach of most research groups and clinical institutions.

To the best of our knowledge, no existing approach has leveraged transformer's self-attention mechanism for MIL aggregation and enabled task adaptation of large-scale PFMs on a single GPU for downstream clinical applications, while addressing the optimization challenges that arise when jointly training foundation models and MIL aggregators.

# 3 Methodology

#### 3.1 Problem Formulation

Let  $X=\{x_1,x_2,...,x_K\}$  represent an H&E stained WSI composed of K non-overlapping tiles, where each tile  $x_i \in \mathbb{R}^{H \times W \times C}$  corresponds to the tissue region extracted from the WSI. For MIL, a cancer patient's WSI has a bag-level label  $y \in \{0,1\}$  for binary classification tasks (e.g., presence or absence of a gene mutation in a patient), but no tile-level annotations. Our goal is to adapt a pretrained PFM  $f_{\theta}$ , parameterized by  $\theta$ , to extract tile-level features that are relevant for a downstream task. A ViT [4] based PFM maps each tile to a feature vector  $z_i = f_{\theta}(x_i) \in \mathbb{R}^D$  [5, 8, 9] by first diving each input tile into a grid of N non-overlapping patches (tokens) of size  $P \times P$ , with an additional learnable CLS token prepended to the sequence. These tokens are linearly projected and embedded with position information before being processed through multiple self-attention layers to compute tile feature representations.

# 3.2 Attention-Based Aggregation

The CLS token attends to all other tokens, to compute attention weights that indicate the importance of each token for the feature representation. We propose to leverage these attention weights for MIL aggregation. For a WSI with K tiles, let  $\mathbf{Z} = [z_1^T, z_2^T, \dots, z_K^T]^T \in \mathbb{R}^{K \times D}$  denote the feature matrix, where each row  $z_i \in \mathbb{R}^D$  is the feature vector (CLS token embedding) for tile i. Similarly, let  $\mathbf{a} = [a_1, a_2, \dots, a_K]^T \in \mathbb{R}^K$  denote the vector of attention weights derived from the ViT. For each tile  $x_i$ , the attention weight  $a_i$  is computed as:

$$a_i = \frac{1}{H} \sum_{h=1}^{H} \frac{1}{N} \sum_{i=1}^{N} A_{cls,j}^h$$
 (1)

where  $A^h_{cls,j}$  is the attention weight from the CLS token to the  $j^{th}$  token in the  $h^{th}$  attention head while H and N are the numbers of attention heads and tokens, respectively. The proposed approach maintains a separate computation graph for the aggregator by detaching tile features and attention weights from the PFM's computation graph. The detached attention weights undergo min-max scaling to the range [0,1] followed by softmax normalization, ensuring they form a proper probability distribution for tile importance scoring to compute the bag representation Z as:

$$Z = \mathbf{Z}^T \mathbf{a} = \sum_{i=1}^K a_i z_i \tag{2}$$

where both  $\mathbf{Z}$  and  $\mathbf{a}$  are detached from the PFM's computation graph. This ensures that the gradients from the classification loss only flow through the aggregator parameters while keeping the PFM's parameters fixed during this stage of optimization. The bag representation Z is then passed through a linear classifier to predict the bag-level label:

$$\hat{y} = \sigma(WZ + b) \tag{3}$$

where  $\sigma$  is the sigmoid activation while  $W \in \mathbb{R}^{1 \times D}$  and  $b \in \mathbb{R}$  are aggregator parameters  $\theta_{agg}$ :  $\{W,b\}$ , that are learned during backpropagation with weighted cross-entropy loss:

$$\mathcal{L}_{agg}(y, \hat{y}) = -w_y [y \log(\hat{y}) + (1 - y) \log(1 - \hat{y})]$$
(4)

where  $w_y$  is the weight assigned to class y to handle class imbalance.

## 3.3 PFM Adaptation

Instead of employing conventional end-to-end backpropagation, we propose to detach gradients from the aggregator's computation graph to formulate a dedicated loss function for PFM adaptation.

**Feature Alignment Loss:** Let us define  $\mathbf{G}_z = [g_{z_1}^T, g_{z_2}^T, \dots, g_{z_K}^T]^T \in \mathbb{R}^{K \times D}$  as the feature gradient matrix where  $k^{th}$  row contains the gradient of the aggregator loss (equation 4) with respect to the corresponding tile's feature vector. During backpropagation through the aggregator, the gradients with respect to each feature vector are automatically computed (by chain rule) based on their contribution to the bag representation as  $g_{z_i} = \frac{\partial \mathcal{L}_{agg}}{\partial z_i} = a_i \frac{\partial \mathcal{L}_{agg}}{\partial Z}$ . We propose to detach the feature gradients from the aggregator's computation graph to compute the feature alignment loss as:

$$\mathcal{L}_{feature} = -\text{tr}(\mathbf{Z}\mathbf{G}_z^T) = \sum_{i=1}^K \langle z_i, g_{z_i} \rangle = \sum_{i=1}^K \sum_{d=1}^D z_{i,d} \times g_{z_i,d}$$
 (5)

This loss guides feature vectors to move in the direction that reduces the classification loss and can be interpreted as a first-order approximation of the effect of feature changes on the aggregator loss.

**Attention Loss:** Let us define the gradient of the aggregator loss with respect to attention weights as  $\mathbf{g}_a = [g_{a_1}, g_{a_2}, \dots, g_{a_K}]^T \in \mathbb{R}^K$ . Similar to the feature gradients, the gradient of the aggregator loss with respect to each attention weight is automatically computed by the chain rule as  $g_{a_i} = \frac{\partial \mathcal{L}_{agg}}{\partial a_i} = \langle z_i, \frac{\partial \mathcal{L}_{agg}}{\partial Z} \rangle$ . We propose to compute the attention loss using the detached attention gradient as:

$$\mathcal{L}_{attention} = \mathbf{a}^T \mathbf{g}_a = \sum_{i=1}^K a_i \times g_{a_i}$$
 (6)

This loss encourages attention weights to adjust based on the informativeness of each tile for the downstream task, increasing (or decreasing) weights for informative (or uninformative) tiles.

Task Adaptation Loss (TAL): For PFM updates, TAL combines the feature and the attention loss:

$$\mathcal{L}_{PFM} = \mathcal{L}_{feature} + \lambda \mathcal{L}_{attention} \tag{7}$$

where  $\lambda$  is the hyperparameter that controls the relative importance of the attention loss. The PFM parameters,  $\theta_{PFM}$ , are then updated with the backpropagation using its own loss:  $\mathcal{L}_{PFM}$ . The training procedure for the proposed approach is presented in Algorithm 1 with illustraion shown in Figure 2 and its implementation is available at https://github.com/pfmadaptation/tapfm/.

## 3.4 Theoretical Analysis

The key innovation in our approach lies in the decoupling of the optimization process. In conventional end-to-end training with a unified computational graph, gradients flow through both the PFM and aggregator simultaneously:

$$\nabla_{\theta_{agg},\theta_{PFM}} \mathcal{L} = \left( \frac{\partial \mathcal{L}_{agg}}{\partial \hat{y}} \cdot \frac{\partial \hat{y}}{\partial \theta_{agg}}, \frac{\partial \mathcal{L}_{agg}}{\partial \hat{y}} \cdot \frac{\partial \hat{y}}{\partial Z} \cdot \left( \frac{\partial Z}{\partial \mathbf{Z}} \cdot \frac{\partial \mathbf{Z}}{\partial \theta_{PFM}} + \frac{\partial Z}{\partial \mathbf{a}} \cdot \frac{\partial \mathbf{a}}{\partial \theta_{PFM}} \right) \right)$$
(8)

## Algorithm 1 Task Adaptation of Pathology Foundation Models (TAPFM)

```
1: Input: Dataset \mathcal{D} of WSIs and labels \{(X_b, y_b)\}_{b=1}^M, pretrained pathology foundation model
      f_{\theta_{PFM}}, MIL aggregator f_{\theta_{agg}}, learning rates (\eta_{agg} and \eta_{PFM})
     for epoch = 1 to num_epochs do
 3:
          for each (X_b, y_b) in \mathcal{D} do
              Extract K tiles \{x_1, x_2, ..., x_K\} from X_b as tensor \mathbf{X} \in \mathbb{R}^{H \times W \times C \times K}
 4:
 5:
              // PFM forward pass
              (\mathbf{Z}, \mathbf{A}) = f_{\theta}(\mathbf{X}) {Extract last layer CLS feature and attention matrices}
 6:
              Compute \mathbf{a} = [a_1, a_2, \dots, a_K]^T \in \mathbb{R}^K where, a_i = \frac{1}{H} \sum_{h=1}^H \frac{1}{N} \sum_{j=1}^N A_{cls,j}^h {Average
 7:
              CLS attention across heads and tokens}
 8:
              // Detach features and attention from PFM computation graph
              \mathbf{Z}_{detached} = \text{detach}(\mathbf{Z}) \{ \text{Detach feature matrix} \}
 9:
              \mathbf{a}_{detached} = \text{detach}(\mathbf{a}) \{ \text{Detach attention vector} \}
10:
11:
              // Aggregator parameter update
12:
              \mathbf{a}_{detach\underline{e}d} = \operatorname{softmax}(\operatorname{minmax}(\mathbf{a}_{detached})) \{ \text{Scale to } [0,1] \text{ range and normalize} \}
13:
              Z = \mathbf{Z}^T \mathbf{a} {Compute Bag representation}
14:
              Compute \hat{y} = f_{\theta_{agg}}(z) and \mathcal{L}_{agg} (equation 4)
             Backpropagate: \theta_{agg} \leftarrow \theta_{agg} - \eta_{agg} \nabla_{\theta} \mathcal{L}_{agg} 

// Detach gradients from aggregator computation graph

\mathbf{G}_z^{detached} = \operatorname{detach}(\mathbf{G}_z) {Detach feature gradient matrix}

\mathbf{g}_a^{detached} = \operatorname{detach}(\mathbf{g}_a) {Detach attention gradient vector}
15:
16:
17:
18:
19:
              // PFM fine-tuning with detached gradients
20:
              Compute fine-tuning loss \mathcal{L}_{PFM} (Section 3.3)
              Backpropagate: \theta_{PFM} \leftarrow \theta_{PFM} - \eta_{PFM} \nabla_{\theta_{PFM}} \mathcal{L}_{PFM}
21:
22:
23: end for
24: return Fine-tuned PFM (f_{\theta_{PFM}}) and trained MIL aggregator (f_{\theta_{agg}})
```

TAPFM instead implements the following two-stage optimization:

$$\nabla_{\theta_{agg}} \mathcal{L}_{agg} = \frac{\partial \mathcal{L}_{agg}}{\partial \hat{y}} \cdot \frac{\partial \hat{y}}{\partial \theta_{agg}} \quad \text{(Stage 1: Aggregator Update)} \tag{9}$$

$$\nabla_{\theta_{PFM}} \mathcal{L}_{PFM} = \operatorname{detach}\left(\frac{\partial \mathcal{L}_{agg}}{\partial Z}\right) \cdot \left(\frac{\partial Z}{\partial \mathbf{a}} \cdot \frac{\partial \mathbf{a}}{\partial \theta_{PFM}} + \frac{\partial Z}{\partial \mathbf{Z}} \cdot \frac{\partial \mathbf{Z}}{\partial \theta_{PFM}}\right) (\operatorname{Stage 2: PFM Update})$$
(10)

This design resolves the circular dependency challenge in jointly optimizing PFM and MIL aggregator parameters by detaching gradients between optimization stages, that would otherwise create unstable training dynamics.

**Proposition 1** (Gradient Stabilization). The TAPFM approach breaks the circular dependency at each iteration t by enforcing:

$$\frac{\partial \mathcal{L}_{agg}}{\partial \theta_{agg}}|_{t} \propto g(\theta_{PFM_{t-1}}, \theta_{agg_{t-1}}) \quad and \quad \frac{\partial \mathcal{L}_{PFM}}{\partial \theta_{PFM}}|_{t} \propto f(\theta_{PFM_{t-1}}, \theta_{agg_{t}})$$
(11)

resulting in more stable parameter trajectories than joint optimization.

*Proof.* In joint optimization, the parameter updates create an implicit feedback loop:

$$\theta_{PFM_t} = \theta_{PFM_{t-1}} - \eta_{PFM} \nabla_{\theta_{PFM}} \mathcal{L}_{agg}(\theta_{PFM_{t-1}}, \theta_{agg_{t-1}})$$
(12)

$$\theta_{aqq_t} = \theta_{aqq_{t-1}} - \eta_{aqq} \nabla_{\theta_{aqq}} \mathcal{L}_{aqq} (\theta_{PFM_t}, \theta_{aqq_{t-1}})$$
(13)

Note that  $\theta_{agg_t}$  depends on  $\theta_{PFM_t}$ , which itself depends on  $\theta_{agg_{t-1}}$ . This creates a circular dependency where each parameter set is chasing a moving target. However, the proposed approach breaks this loop by detaching the gradient computation graphs:




Figure 2: TAPFM Algorithm Overview - The proposed approach passes WSI tiles through a PFM to extract (last layer) CLS features Z and attention weights a (solid arrows). These are detached from the PFM's computation graph and used by the MIL aggregator to compute bag-level predictions and aggregator loss  $\mathcal{L}_{aqq}$  (solid arrows). During backpropagation (dashed arrows), gradients from  $\mathcal{L}_{agg}$  are detached to formulate the task adaptation loss  $\mathcal{L}_{PFM}$  (equation 7) for fine-tuning PFM parameters, while aggregator parameters are updated using  $\mathcal{L}_{agg}$ . This dual-optimization approach with separate computational graphs enables task adaptation on a single GPU.

$$\theta_{aggt} = \theta_{aggt-1} - \eta_{agg} \nabla_{\theta_{agg}} \mathcal{L}_{agg} (\text{detach}(\theta_{PFM_{t-1}}), \theta_{aggt-1})$$

$$\theta_{PFM_t} = \theta_{PFM_{t-1}} - \eta_{PFM} \nabla_{\theta_{PFM}} \mathcal{L}_{PFM} (\theta_{PFM_{t-1}}, \text{detach}(\theta_{agg_t}))$$
(15)

$$\theta_{PFM_t} = \theta_{PFM_{t-1}} - \eta_{PFM} \nabla_{\theta_{PFM}} \mathcal{L}_{PFM} (\theta_{PFM_{t-1}}, \text{detach}(\theta_{agg_t}))$$
 (15)

This detaching operation ensures that during aggregator optimization,  $\theta_{PFM}$  is treated as a constant, and during PFM optimization, the updated  $\theta_{agg}$  influences the loss but does not receive gradient updates. This effectively eliminates the circular dependency and stabilizes training.

The stabilization effect of TAPFM's detached-gradient optimization is illustrated by the training-loss variance plots in Figure 5 in Appendix C.Figure 5 shows that when training with a unified computational graph, the loss oscillates without convergence, whereas TAPFM's detached-gradient optimization exhibits smooth exponential decay—confirming the theoretical stability analysis presented in this section. Additional properties of the proposed Algorithm 1 are elaborated in the appendix: permutation invariance (Appendix A.1), computational and space complexity analysis(Appendix A.2) and A.3), and prevention of catastrophic forgetting during task adaptation (Appendix A.4).

#### 3.5 Multi-label Classification

The proposed Algorith 1 can be easily adapted for multi-label classification problems where each patient can be associated with multiple binary labels. Let  $y = [y^1, y^2, ..., y^C]$  represent the ground truth vector where  $y^j \in \{0, 1\}$  indicates the presence or absence of the j-th mutation. The aggregator loss for each class is computed using the weighted cross-entropy loss as in Equation 4. Note that the each output node in MIL aggregator is considered as class-specific binary predictor for multi-label classification. The total aggregator loss is then formulated as a weighted sum  $\mathcal{L}_{agg} = \sum_{j=1}^{C} \alpha_j \mathcal{L}_{agg}^j$ , where  $\alpha_j$  is the weight assigned to class j, calculated as the inverse of the ratio of positive examples of that class to the total number of training instances.

Noticeably, multi-label classification differs fundamentally from both binary and multi-class approaches. While multi-class classification assumes mutual exclusivity among classes (one-hot encoding), multi-label classification allows multiple concurrent positive labels, better reflecting clinical reality where tumors can harbor multiple actionable mutations simultaneously [33]. This

is particularly relevant in scenarios such as collision tumors [34] and resistance-driven secondary mutations [35], where combinations of mutations have distinct prognostic implications [36].

While the methodology presented in this paper primarily focuses on classification tasks, TAPFM's core approach generalizes to other clinically relevant objectives as well. By replacing the classification head (Equation 4) with task-specific layers (e.g., Multi-task logistic regression for survival prediction [37]) and corresponding loss functions, TAPFM can adapt PFMs for survival analysis tasks while maintaining single-GPU training efficiency. Additional survival prediction experiments illustrating this generalization are provided in Appendix D.2.

# 4 Experiments

The proposed TAPM approach is evaluated on clinically relevant mutation prediction tasks using institutional and public cohorts of bladder cancer (BLCA) and lung adenocarcinoma (LUAD) patients.

**Datasets**: The institutional dataset consists of H&E WSIs of 2,030 BLCA and 8,820 LUAD patients collected during routine clinical care at Memorial Sloan Kettering Cancer Center (MSKCC), including both  $20\times$  and  $40\times$  ( $\sim 30\%$  of all WSIs in each cohort) magnifications to reflect real-world data acquisition variability. WSIs from The Cancer Genome Atlas (TCGA) cohorts – TCGA-BLCA (260 patients) and TCGA-LUAD (438 patients), all scanned at  $40\times$  resolution, are exclusively used for external validation to assess generalizability of the proposed approach. Only one WSI per patient is used in all training and validation cohorts.

For the binary classification task, TAPM is evaluated on two clinically relevant mutation prediction tasks: *FGFR3* in BLCA and *EGFR* in LUAD. For multi-label classification, TAPM's ability to simultaneously predict four actionable mutations in LUAD patients is assessed: *EGFR*, *KRAS*, *MET*, and *ALK*. The prevalence rate of these mutations across institutional (TCGA) cohorts are: 16% (14%) for *FGFR3* in BLCA, and in LUAD: 26% (14%) for *EGFR*, 27% (35%) for *KRAS*, 4% (2%) for *MET*, and 3% (1%) for *ALK*.

**Benchmarks**: We evaluate state-of-the-art PFMs such as **UNI** [5], **GigaPath** [8], and **H-Optimus-0** [9]. Motivated by prior findings that lightweight MIL models can attain clinical performance comparable to computationally expensive aggregators [28], this work employs memory-efficient MIL methods on single-GPU systems: **ABMIL** [2], **DSMIL** [24], **CLAM** [10], and **VarMIL** [25].

Implementation Details: All reported experiments in this paper are conducted using PyTorch 2.5.1 on a single NVIDIA H100 (80GB memory). Each WSI is processed at native resolution  $(20 \times \text{ or } 40 \times)$  to extract non-overlapping tiles in a sliding window manner after filtering out the non-tissue regions with Otsu thresholding [38]. For  $20 \times \text{WSIs}$ , tiles of size  $224 \times 224 \times 3$  pixels are extracted directly, while for  $40 \times$  images, tiles of size  $448 \times 448 \times 3$  pixels are extracted and resized to  $224 \times 224 \times 3$  pixels to maintain consistent spatial context. As detailed in the space complexity analysis (Appendix A.3), the memory requirements of the proposed TAPFM method scale quadratically with the number of tokens (patches) processed by ViTs. Thus, the  $224 \times 224$  tile size is selected as the optimal dimension that prevents out-of-memory errors while maximizing the contextual information captured per tile. During training, 300, 100, and 75 tiles per WSI per epoch are randomly sample without replacement for UNI, Gigapath, and H-Optimus-0 respectively – the maximum number of tiles processable for each PFM on a single H100 GPU while maintaining end-to-end fine-tuning capability. *At inference, all tiles obtained from a given WSI are used for downstream mutation prediction tasks*.

For the proposed TAPFM method  $\lambda=1.0$  is used for all experiments. The institutional cohort is evaluated under 5-fold cross-validation at the patient level. In each fold, patients are stratified by label and scan resolution and split into 80% training, 10% validation, and 10% testing, with no patient overlap across splits. Area Under the receiver operating characteristics Curve (AUC) is the primary metric reported (binary: AUC; multi-label: macro-average AUC). Model selection is performed on the fold-specific validation set. For external validation, each of the 5 fold-specific models trained on the institutional data is evaluated on the corresponding TCGA cohort.

For training, AdamW [39] with weight decay of 1e-4 is used as opitimzer, applying differential learning rates of 1e-6 and 1e-5 for PFM and aggregator parameters, respectively. Training data augmentation included random horizontal flips, random rotations (of 90°, 180°, or 270°), and Gaussian blur. A cosine annealing scheduler with warm restarts ( $T_0 = 10, T_{mult} = 2$ ) is also used for better convergence [40]. Each batch contained 1 WSI, and TAPFM is trained for 20 epochs while

all other benchmarks are trained for 50 epochs, with the institutional validation set used to select the best-performing model for all evaluations on the institutional and TCGA testing sets.

#### 4.1 Results

Table 1 shows the performance comparison of three sets of models on the testing data: (1) fixed-PFM with trained MIL aggregators, (2) fine-tuned PFM and MIL aggregators (equivalent to setting  $\lambda=0$  in equation 7 with external MIL methods), and (3) proposed TAPFM. It is evident that the proposed TAPFM approach outperforms the other benchmarks across both binary mutation prediction tasks. H-Optimus-0 (TAPFM) consistently achieves the best performance across both institutional and external TCGA testing cohorts, followed by Gigapath (TAPFM), indicates generalizability of the proposed approach. Table 2 extends TAPFM evaluation to the more challenging task of simultaneously predicting four actionable mutations in LUAD. H-Optimus-0 (TAPFM) consistently outperforms GigaPath (TAPFM) across all mutations, even for the rate MET and ALK mutations. Area Under Precision-Recall Curve (AUPRC) values are reported in Appendix D.1.

## 4.2 Runtime Performance

Training times for BLCA are 12 hours for UNI, 21 hours for Gigapath, and 24 hours for H-Optimus-0. For LUAD cases, training required 2 days 4 hours for UNI, 4 days 2 hours for Gigapath, and 4 days 6 hours for Hoptimus. Inference times per WSI are 4.85 minutes for UNI, 6.38 minutes for Gigapath, and 7.15 minutes for H-Optimus-0. These results confirm that TAPFM enables efficient PFM task adaptation on standard hardware making it suitable for clinical implementation.

#### 4.3 Convergence

For binary *FGFR3* classification in BLCA, Figure 3a shows UNI reaching maximum validation performance by epoch 6 (AUC 0.8542), Gigapath by epoch 5 (AUC 0.8764), and H-Optimus-0 by epoch 7 (AUC 0.8960). Additionally, experiments on LUAD datasets (not shown) demonstrated that all PFMs converge within 4 epochs for binary classification tasks. For multi-label LUAD classification, convergence occurred at epoch 8 for UNI, epoch 10 for Gigapath and epoch 11 for H-Optimus-0. Loss-variance comparisons between joint optimization and TAPFM's detached-gradient training are shown in Appendix 5, illustrating markedly smoother convergence and confirming the theoretical stability analysis presented in Section 3.4.




Figure 3: For bianry *FGFR3* prediction task in BLCA – (a) validation AUC trajectories of various TAPFM models, and the variation of log-transformed training loss of the H-Optimus-0 (TAPFM) model with (b) attention loss weighting ( $\lambda$ ) and (c) tile sampling density.

## 4.4 Ablation Studies

Systematic ablation studies investigate the influence of key hyperparameters – attention loss weighting ( $\lambda$  in equation 7) and number of tiles sampled per WSI per epoch – on the performance of H-Optimus-0 (TAPFM) model for the binary *FGFR3* prediction task in BLCA patients.

**Lambda**: To evaluate the impact of the attention loss term in TAL (Equation 7), log-linear convergence fits of the form  $\log \mathcal{L}_k = a + b \, k$  were computed over epochs k = 2 to 20. Log-transformed loss fits are shown in Figure 3b, with raw curves in Appendix 4a. All values of  $\lambda$  yielded consistent exponential decay, with convergence rates of b = -0.0701 ( $R^2 = 0.9737$ ), -0.0718 ( $R^2 = 0.9808$ ), -0.0706 ( $R^2 = 0.9765$ ), and -0.0810 ( $R^2 = 0.9693$ ) for  $\lambda \in \{0.25, 0.5, 0.75, 1.0\}$ , respectively.

Table 1: Performance comparison of different PFM and MIL aggregation methods for binary classification tasks in terms of AUC (mean  $\pm$  95% CI from 5-fold cross-validation). N indicates the number of patients in each cohort. Best and second best models are in bold and underlined text, respectively.

Model	BLCA FO	FR3	LUAD EGFR			
1VIOLE1		TCGA $(N = 260)$		TCGA $(N = 438)$		
Fixed-PFM with Trained MIL Aggregators						
UNI + DSMIL	$0.7876 \pm 0.024$	$0.7928 \pm 0.022$	$0.7352 \pm 0.021$	$0.7624 \pm 0.025$		
UNI + CLAM	$0.7893 \pm 0.023$	$0.7912 \pm 0.024$	$0.7389 \pm 0.022$	$0.7645 \pm 0.024$		
UNI + VarMIL	$0.7912 \pm 0.022$	$0.7948 \pm 0.021$	$0.7414 \pm 0.020$	$0.7663 \pm 0.023$		
UNI + ABMIL	$0.7904 \pm 0.023$	$0.7962 \pm 0.023$	$0.7396 \pm 0.021$	$0.7718 \pm 0.022$		
GigaPath + DSMIL	$0.8232 \pm 0.021$	$0.8645 \pm 0.019$	$0.7657 \pm 0.020$	$0.8153 \pm 0.022$		
GigaPath + CLAM	$0.8246 \pm 0.020$	$0.8673 \pm 0.018$	$0.7672 \pm 0.019$	$0.8164 \pm 0.021$		
GigaPath + VarMIL	$0.8274 \pm 0.019$	$0.8689 \pm 0.018$	$0.7691 \pm 0.018$	$0.8192 \pm 0.020$		
GigaPath + ABMIL	$0.8294 \pm 0.019$	$0.8712 \pm 0.017$	$0.7711 \pm 0.019$	$0.8205 \pm 0.019$		
H-Optimus-0 + DSMIL	$0.8365 \pm 0.020$	$0.8731 \pm 0.018$	$0.7694 \pm 0.019$	$0.8237 \pm 0.021$		
H-Optimus-0 + CLAM	$0.8373 \pm 0.019$	$0.8752 \pm 0.017$	$0.7713 \pm 0.018$	$0.8253 \pm 0.020$		
H-Optimus-0 + VarMIL	$0.8401 \pm 0.018$	$0.8774 \pm 0.016$	$0.7735 \pm 0.018$	$0.8282 \pm 0.019$		
H-Optimus-0 + ABMIL	$0.8412 \pm 0.018$	$0.8786 \pm 0.017$	$0.7742 \pm 0.017$	$0.8295 \pm 0.018$		
Fine-tuned (FT) PFM with MI	L Aggregators					
UNI + DSMIL (FT)	$0.8132 \pm 0.023$	$0.8209 \pm 0.021$	$0.7526 \pm 0.022$	$0.7837 \pm 0.024$		
UNI + CLAM (FT)	$0.8147 \pm 0.022$	$0.8223 \pm 0.020$	$0.7542 \pm 0.021$	$0.7865 \pm 0.023$		
UNI + VarMIL (FT)	$0.8176 \pm 0.021$	$0.8252 \pm 0.020$	$0.7568 \pm 0.020$	$0.7894 \pm 0.022$		
UNI + ABMIL (FT)	$0.8193 \pm 0.021$	$0.8237 \pm 0.021$	$0.7581 \pm 0.021$	$0.7922 \pm 0.021$		
GigaPath + DSMIL (FT)	$0.8372 \pm 0.020$	$0.8831 \pm 0.017$	$0.7986 \pm 0.019$	$0.8351 \pm 0.020$		
GigaPath + CLAM (FT)	$0.8381 \pm 0.019$	$0.8847 \pm 0.016$	$0.8012 \pm 0.018$	$0.8377 \pm 0.019$		
GigaPath + VarMIL (FT)	$0.8407 \pm 0.018$	$0.8873 \pm 0.015$	$0.8043 \pm 0.017$	$0.8408 \pm 0.018$		
GigaPath + ABMIL (FT)	$0.8393 \pm 0.019$	$0.8858 \pm 0.016$	$0.8074 \pm 0.018$	$0.8421 \pm 0.017$		
H-Optimus-0 + DSMIL (FT)	$0.8478 \pm 0.019$	$0.8843 \pm 0.016$	$0.8121 \pm 0.018$	$0.8479 \pm 0.019$		
H-Optimus-0 + CLAM (FT)	$0.8491 \pm 0.018$	$0.8859 \pm 0.015$	$0.8143 \pm 0.017$	$0.8512 \pm 0.018$		
H-Optimus-0 + VarMIL (FT)	$0.8526 \pm 0.017$	$0.8889 \pm 0.014$	$0.8167 \pm 0.016$	$0.8543 \pm 0.017$		
H-Optimus-0 + ABMIL (FT)	$0.8512 \pm 0.018$	$0.8874 \pm 0.015$	$0.8189 \pm 0.017$	$0.8529 \pm 0.016$		
Proposed TAPFM method						
UNI (TAPFM)	$0.8415 \pm 0.021$	$0.8536 \pm 0.019$	$0.8175 \pm 0.018$	$0.8309 \pm 0.020$		
Gigapath (TAPFM)	$0.8624 \pm 0.016$	$0.8881 \pm 0.013$	$0.8376 \pm 0.015$	$0.8482 \pm 0.009$		
H-Optimus-0 (TAPFM)	$\textbf{0.8837} \pm \textbf{0.018}$	$0.8956 \pm 0.011$	$0.8503 \pm 0.013$	$0.8590 \pm 0.010$		

Table 2: Performance comparison on multi-label classification of actionable mutations in LUAD. Results are reported as AUC (mean  $\pm 95\%$  CI from 5-fold cross-validation). Based on binary classification results (Table 1), only the top performers are shown, as performance varied primarily by foundation model type.

Model	Institutional Cohort $(N=876)$				Macro Average	
1120401	EGFR	KRAS	MET	ALK	ivanero ray er uge	
UNI (TAPFM)	$0.8287 \pm 0.019$	$0.7814 \pm 0.021$	$0.8095 \pm 0.028$	$0.8341 \pm 0.031$	$0.8134 \pm 0.018$	
Gigapath (TAPFM)	$0.8595 \pm 0.015$	$0.8075 \pm 0.018$	$0.8350 \pm 0.024$	$0.8632 \pm 0.026$	$0.8413 \pm 0.014$	
H-Optimus-0 (TAPFM)	$0.8665 \pm 0.018$	$\textbf{0.8153} \pm \textbf{0.019}$	$\textbf{0.8420} \pm \textbf{0.025}$	$\textbf{0.8702} \pm \textbf{0.024}$	$\textbf{0.8485} \pm \textbf{0.017}$	
$\mathbf{TCGA}\ (N=438)$						
UNI (TAPFM)	$0.8342 \pm 0.022$	$0.7896 \pm 0.024$	$0.7913 \pm 0.035$	$0.8287 \pm 0.038$	$0.8110 \pm 0.021$	
GigaPath (TAPFM)	$0.8603 \pm 0.018$	$0.8147 \pm 0.020$	$0.8179 \pm 0.029$	$0.8540 \pm 0.032$	$0.8367 \pm 0.021$	
H-Optimus-0 (TAPFM)	$\textbf{0.8629} \pm \textbf{0.017}$	$\textbf{0.8226} \pm \textbf{0.019}$	$\textbf{0.8241} \pm \textbf{0.030}$	$0.8563 \pm 0.034$	$0.8415 \pm 0.016$	

Although convergence behavior remained stable across this range, increasing  $\lambda$  produced steeper decay and lower final training loss, with the best performance observed at  $\lambda=1.0$ . These results suggest that stronger weighting of the TAL attention supervision improves training efficiency without compromising stability.

Number of tiles: Figure 3c shows that increasing the number of tiles per WSI consistently improved the performance of H-Optimus-0 (TAPFM) model (raw loss curves in Appendix 4b). Another exponential decay model,  $\log \mathcal{L}_k = a + b \, k$ , was fit to training loss curves over epochs k=2 to 20, with estimated convergence rates of b=-0.0532 ( $R^2=0.9731$ ), -0.0569 ( $R^2=0.9811$ ), and -0.0725 ( $R^2=0.9752$ ) for models trained with 25, 50, and 75 tiles per WSI, respectively. The 75-tile model converged by epoch 7 with a validation AUC of 0.8960, while the 50-tile model reached 0.8764 by the same epoch. The 25-tile variant (TAPFM H-Optimus-0) converged earlier—by epoch 5—but plateaued at a lower AUC of 0.8527. These findings indicate that denser tile sampling both accelerates convergence and improves performance on the institutional validation set.

Experimental analysis of incorporating a cosine regularization term (see Appendix A.5) for feature alignment loss in equation 7 revealed no significant variation in FGFR3 prediction performance. Consequently,  $\lambda=1.0$  and the maximum number of tiles per WSI per epoch that could be accommodated on a single GPU for each PFM are used in all LUAD experiments

# 5 Clinical Impact

Because LUAD harbors a large number of drug-targetable mutations, molecular diagnostics are especially valuable for guiding its targeted therapies [41, 42]. LUAD was the first tumor type to develop official guidelines recommending universal EGFR and ALK testing [43], which were subsequently expanded in 2018 to include additional actionable genes when sufficient tissue is available [44]. One of the principal challenges remains obtaining adequate DNA from small core biopsies to perform this extensive molecular workup [45]. Although this paradigm has been embraced in LUAD, other malignancies such as BLCA have been sequenced far less frequently outside major centers despite the availability of FGFR3-directed therapies [46]. The ability to predict actionable mutations directly from H&E-stained WSIs promises to streamline and economize current diagnostic workflows. By triaging or potentially obviating the need for costly and tissue-requiring molecular assays, TAPFM can help overcome the infrastructure and financial barriers that preclude precision oncology in resource-limited settings. Even when resources are available, TAPFM offers inference that can be performed as soon as the digital image is scanned. Therefore, clinicians can receive molecularly informed results within hours instead of days/weeks. This study demonstrates that a single model (TAPFM) can simultaneously detect multiple targetable mutations in LUAD, and that its performance generalizes from the originating institution to an independent TCGA cohort.

# 6 Conclusion

This work introduces TAPFM, a novel approach for adapting PFMs to specific clinical tasks by leveraging ViT's attention mechanism for MIL aggregation and a detached dual-gradient approach for updating PFM parameters on a single GPU. TAPFM bridges the gap between self-supervised pretraining and supervised downstream adaptation in computational pathology, enabling more effective use of PFMs for clinical applications. The experimental results establish its effectiveness for clinically relevant mutation prediction tasks for BLCA (FGFR3) and LUAD (EGFR, KRAS, MET, ALK) patients while maintaining computational efficiency. Notably, TAPFM successfully tackles the challenging task of simultaneous prediction of four actionable mutations in LUAD patients, maintaining reasonable performance even for rare mutations like MET and ALK. Despite promising results, certain limitations of this work can be addressed in future studies. The approach shows potential for extension to additional clinical endpoints including survival analysis, recurrence prediction, and treatment response estimation. Investigations into which specific transformer layers benefit most from task adaptation could optimize the approach by selectively updating only those parameters. Additional external validation across multi-institutional cohorts with diverse scanning protocols and expanded biomarker panels would strengthen the clinical utility of the proposed approach. Implementations that scale to distributed training across multiple GPUs to increase the number of tiles processed per WSI during training may enhance TAPFM's generalization performance.

# Acknowledgments

We thank the research funding provided by a Cancer Center Support Grant from the NIH/NCI (grant number P30CA008748) and the Warren Alpert Foundation through the Warren Alpert Center for

Digital and Computational Pathology at Memorial Sloan Kettering Cancer Center. We also thank Swaraj Nanda, Siddharth Singi, Jamal Benhamida, David Kim, Jie-Fu Chen, Amir Momeni-Boroujeni, Gregory M. Goldgof, and Gabriele Campanella for their contributions to data curation, experiment design, and manuscript preparation.

## References

- [1] Andrew H Song, Guillaume Jaume, Drew FK Williamson, Ming Y Lu, Anurag Vaidya, Tiffany R Miller, and Faisal Mahmood. Artificial intelligence for digital and computational pathology. *Nature Reviews Bioengineering*, 1(12):930–949, 2023.
- [2] Maximilian Ilse, Jakub Tomczak, and Max Welling. Attention-based deep multiple instance learning. In *International Conference on Machine Learning*, pages 2127–2136. PMLR, 2018.
- [3] Gabriele Campanella, Matthew G. Hanna, Luke Geneslaw, Allen Miraflor, Vitor Werneck Krauss Silva, Klaus J. Busam, Edi Brogi, Victor E. Reuter, David S. Klimstra, and Thomas J. Fuchs. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images. *Nature Medicine*, 25(8):1301–1309, 2019.
- [4] Alexey Dosovitskiy, Lucas Beyer, Alexander Kolesnikov, Dirk Weissenborn, Xiaohua Zhai, Thomas Unterthiner, Mostafa Dehghani, Matthias Minderer, Georg Heigold, Sylvain Gelly, Jakob Uszkoreit, and Neil Houlsby. An image is worth 16x16 words: Transformers for image recognition at scale. In *International Conference on Learning Representations*, 2021.
- [5] Richard J Chen, Tong Ding, Ming Y Lu, Drew FK Williamson, Guillaume Jaume, Andrew H Song, Bowen Chen, Andrew Zhang, Daniel Shao, Muhammad Shaban, et al. Towards a general-purpose foundation model for computational pathology. *Nature Medicine*, 30(3):850–862, 2024.
- [6] Eugene Vorontsov, Alican Bozkurt, Adam Casson, George Shaikovski, Michal Zelechowski, Kristen Severson, Eric Zimmermann, James Hall, Neil Tenenholtz, Nicolo Fusi, et al. A foundation model for clinical-grade computational pathology and rare cancers detection. *Nature medicine*, 30(10):2924–2935, 2024.
- [7] Eric Zimmermann, Eugene Vorontsov, Julian Viret, Adam Casson, Michal Zelechowski, George Shaikovski, Neil Tenenholtz, James Hall, David Klimstra, Razik Yousfi, et al. Virchow2: Scaling self-supervised mixed magnification models in pathology. arXiv preprint arXiv:2408.00738, 2024.
- [8] Hanwen Xu, Naoto Usuyama, Jaspreet Bagga, Sheng Zhang, Rajesh Rao, Tristan Naumann, Cliff Wong, Zelalem Gero, Javier González, Yu Gu, et al. A whole-slide foundation model for digital pathology from real-world data. *Nature*, 630(8015):181–188, 2024.
- [9] Bioptimus. H-optimus-0: A foundational model for histopathology. https://github.com/bioptimus/releases/tree/main/models/h-optimus/v0, 2024. Accessed: April 2025.
- [10] M. Y. Lu, D. F. K. Williamson, T. Y. Chen, R. J. Chen, M. Barbieri, and F. Mahmood. Data-efficient and weakly supervised computational pathology on whole-slide images. *Nature Biomedical Engineering*, 5(6):555–570, 2021.
- [11] Faisal Mahmood. A benchmarking crisis in biomedical machine learning. *Nature Medicine*, pages 1–1, 2025.
- [12] Saghir Alfasly, Ghazal Alabtah, Sobhan Hemati, Krishna Rani Kalari, Joaquin J Garcia, and HR Tizhoosh. Validation of histopathology foundation models through whole slide image retrieval. *Scientific Reports*, 15(1):3990, 2025.
- [13] Gabriele Campanella, Shengjia Chen, Manbir Singh, Ruchika Verma, Silke Muehlstedt, Jennifer Zeng, Aryeh Stock, Matt Croken, Brandon Veremis, Abdulkadir Elmas, et al. A clinical benchmark of public self-supervised pathology foundation models. *Nature Communications*, 16(1):3640, 2025.
- [14] Xiyue Wang, Sen Yang, Jun Zhang, Minghui Wang, Jing Zhang, Wei Yang, Junzhou Huang, and Xiao Han. Transformer-based unsupervised contrastive learning for histopathological image classification. *Medical image analysis*, 81:102559, 2022.
- [15] Richard J Chen, Chengkuan Chen, Yicong Li, Tiffany Y Chen, Andrew D Trister, Rahul G Krishnan, and Faisal Mahmood. Scaling vision transformers to gigapixel images via hierarchical self-supervised learning. In *Proceedings of the IEEE/CVF conference on computer vision and pattern recognition*, pages 16144–16155, 2022.

- [16] Shekoofeh Azizi, Laura Culp, Jan Freyberg, Basil Mustafa, Sebastien Baur, Simon Kornblith, Ting Chen, Nenad Tomasev, Jovana Mitrović, Patricia Strachan, et al. Robust and data-efficient generalization of self-supervised machine learning for diagnostic imaging. *Nature Biomedical Engineering*, 7(6):756–779, 2023.
- [17] Mathilde Caron, Hugo Touvron, Ishan Misra, Hervé Jégou, Julien Mairal, Piotr Bojanowski, and Armand Joulin. Emerging properties in self-supervised vision transformers. In *Proceedings of the IEEE/CVF International Conference on Computer Vision*, pages 9650–9660, 2021.
- [18] Alexandre Filiot, Ridouane Ghermi, Antoine Olivier, Paul Jacob, Lucas Fidon, Axel Camara, Alice Mac Kain, Charlie Saillard, and Jean-Baptiste Schiratti. Scaling self-supervised learning for histopathology with masked image modeling. medRxiv, pages 2023–07, 2023.
- [19] Maxime Oquab, Timothée Darcet, Théo Moutakanni, Huy V. Vo, Marc Szafraniec, Vasil Khalidov, Pierre Fernandez, Daniel HAZIZA, Francisco Massa, Alaaeldin El-Nouby, Mido Assran, Nicolas Ballas, Wojciech Galuba, Russell Howes, Po-Yao Huang, Shang-Wen Li, Ishan Misra, Michael Rabbat, Vasu Sharma, Gabriel Synnaeve, Hu Xu, Herve Jegou, Julien Mairal, Patrick Labatut, Armand Joulin, and Piotr Bojanowski. DINOv2: Learning robust visual features without supervision. *Transactions on Machine Learning Research*, 2024. Featured Certification.
- [20] Ming Y Lu, Bowen Chen, Drew FK Williamson, Richard J Chen, Ivy Liang, Tong Ding, Guillaume Jaume, Igor Odintsov, Long Phi Le, Georg Gerber, et al. A visual-language foundation model for computational pathology. *Nature Medicine*, 30(3):863–874, 2024.
- [21] George Shaikovski, Adam Casson, Kristen Severson, Eric Zimmermann, Yi Kan Wang, Jeremy D Kunz, Juan A Retamero, Gerard Oakley, David Klimstra, Christopher Kanan, et al. Prism: A multi-modal generative foundation model for slide-level histopathology. arXiv preprint arXiv:2405.10254, 2024.
- [22] Jinxi Xiang, Xiyue Wang, Xiaoming Zhang, Yinghua Xi, Feyisope Eweje, Yijiang Chen, Yuchen Li, Colin Bergstrom, Matthew Gopaulchan, Ted Kim, et al. A vision–language foundation model for precision oncology. *Nature*, pages 1–10, 2025.
- [23] Kevin M Boehm, Omar SM El Nahhas, Antonio Marra, Michele Waters, Justin Jee, Lior Braunstein, Nikolaus Schultz, Pier Selenica, Hannah Y Wen, Britta Weigelt, et al. Multimodal histopathologic models stratify hormone receptor-positive early breast cancer. *Nature Communications*, 16(1):2106, 2025.
- [24] Bin Li, Yin Li, and Kevin W Eliceiri. Dual-stream multiple instance learning network for whole slide image classification with self-supervised contrastive learning. In *Proceedings of the IEEE/CVF conference* on computer vision and pattern recognition, pages 14318–14328, 2021.
- [25] Yoni Schirris, Efstratios Gavves, Iris Nederlof, Hugo Mark Horlings, and Jonas Teuwen. Deepsmile: contrastive self-supervised pre-training benefits msi and hrd classification directly from h&e whole-slide images in colorectal and breast cancer. *Medical Image Analysis*, 79:102464, 2022.
- [26] Zhuchen Shao, Hao Bian, Yang Chen, Yifeng Wang, Jian Zhang, Xiangyang Ji, et al. Transmil: Transformer based correlated multiple instance learning for whole slide image classification. Advances in neural information processing systems, 34:2136–2147, 2021.
- [27] Yi Zheng, Rushin H. Gindra, Emily J. Green, Eric J. Burks, Margrit Betke, Jennifer E. Beane, and Vijaya B. Kolachalama. A graph-transformer for whole slide image classification. *IEEE Transactions on Medical Imaging*, 41(11):3003–3015, 2022.
- [28] Shengjia Chen, Gabriele Campanella, Abdulkadir Elmas, Aryeh Stock, Jennifer Zeng, Alexandros D. Polydorides, Adam J. Schoenfeld, Kuan lin Huang, Jane Houldsworth, Chad Vanderbilt, and Thomas J. Fuchs. Benchmarking embedding aggregation methods in computational pathology: A clinical data perspective. In MICCAI Workshop on Computational Pathology with Multimodal Data (COMPAYL), 2024.
- [29] Honglin Li, Chenglu Zhu, Yunlong Zhang, Yuxuan Sun, Zhongyi Shui, Wenwei Kuang, Sunyi Zheng, and Lin Yang. Task-specific fine-tuning via variational information bottleneck for weakly-supervised pathology whole slide image classification. In *Proceedings of the IEEE/CVF conference on computer vision and* pattern recognition, pages 7454–7463, 2023.
- [30] Gabriele Campanella, Eugene Fluder, Jennifer Zeng, Chad Vanderbilt, and Thomas J Fuchs. Beyond multiple instance learning: Full resolution all-in-memory end-to-end pathology slide modeling. arXiv preprint arXiv:2403.04865, 2024.
- [31] Neeraj Kumar, Swaraj Nanda, Siddharth Singi, Gabriele Campanella, Thomas Fuchs, and Chad Vanderbilt. DEMO: A scalable artificial intelligence framework for rapid EGFR mutation screening in lung cancer. In *GenAI for Health: Potential, Trust and Policy Compliance*, 2024.

- [32] Gabriele Campanella, Neeraj Kumar, Swaraj Nanda, Siddharth Singi, Eugene Fluder, Ricky Kwan, Silke Muehlstedt, Nicole Pfarr, Peter J Schüffler, Ida Häggström, et al. Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection. *Nature Medicine*, pages 1–9, 2025.
- [33] Min-Ling Zhang and Zhi-Hua Zhou. A review on multi-label learning algorithms. *IEEE Transactions on Knowledge and Data Engineering*, 26(8):1819–1837, 2014.
- [34] Mary M Torrez, Khalil Sheibani, and Mohammad A Vasef. Mutually exclusive driver mutations identifies 2 separate primaries in a collision tumor initially interpreted as a solitary lung adenocarcinoma with tumor heterogeneity. *Respiratory Medicine Case Reports*, 47:101986, 2024.
- [35] Xinyu von Buttlar, Joshua E Reuss, Stephen V Liu, and Chul Kim. Eml4-alk rearrangement as a mechanism of resistance to osimertinib in metastatic lung adenocarcinoma: a case report. *JTO Clinical and Research Reports*, 2(6):100179, 2021.
- [36] Michelle Shiller, Melissa Johnson, Robert Auber, and Sandip Pravin Patel. Clinical perspectives on the value of testing for stk11 and keap1 mutations in advanced nsclc. Frontiers in Oncology, 14:1459737, 2024.
- [37] Chun-Nam Yu, Russell Greiner, Hsiu-Chin Lin, and Vickie Baracos. Learning patient-specific cancer survival distributions as a sequence of dependent regressors. Advances in neural information processing systems, 24, 2011.
- [38] Nobuyuki Otsu. A threshold selection method from gray-level histograms. *IEEE Transactions on Systems, Man, and Cybernetics*, 9(1):62–66, 1979.
- [39] Ilya Loshchilov and Frank Hutter. Decoupled weight decay regularization. In *International Conference on Learning Representations*, 2019.
- [40] Ilya Loshchilov and Frank Hutter. Sgdr: Stochastic gradient descent with warm restarts. In *International Conference on Learning Representations*, 2017.
- [41] Alex Friedlaender, Maurice Perol, Giuseppe Luigi Banna, Kaushal Parikh, and Alfredo Addeo. Oncogenic alterations in advanced nsclc: a molecular super-highway. *Biomarker Research*, 12(1):24, 2024.
- [42] Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, and Alex Friedlaender. Oncogenic driver mutations in non-small cell lung cancer: Past, present and future. World Journal of Clinical Oncology, 12(4):217, 2021.
- [43] Neal I Lindeman, Philip T Cagle, Mary Beth Beasley, Dhananjay Arun Chitale, Sanja Dacic, Giuseppe Giaccone, Robert Brian Jenkins, David J Kwiatkowski, Juan-Sebastian Saldivar, Jeremy Squire, et al. Molecular testing guideline for selection of lung cancer patients for egfr and alk tyrosine kinase inhibitors: guideline from the college of american pathologists, international association for the study of lung cancer, and association for molecular pathology. *Journal of Thoracic Oncology*, 8(7):823–859, 2013.
- [44] Neal I Lindeman, Philip T Cagle, Dara L Aisner, Maria E Arcila, Mary Beth Beasley, Eric H Bernicker, Carol Colasacco, Sanja Dacic, Fred R Hirsch, Keith Kerr, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of american pathologists, the international association for the study of lung cancer, and the association for molecular pathology. Archives of pathology & laboratory medicine, 142(3):321–346, 2018.
- [45] Dara L Aisner and Carrie B Marshall. Molecular pathology of non–small cell lung cancer: a practical guide. *American journal of clinical pathology*, 138(3):332–346, 2012.
- [46] Claudia Maria Ascione, Fabiana Napolitano, Daniela Esposito, Alberto Servetto, Stefania Belli, Antonio Santaniello, Sarah Scagliarini, Felice Crocetto, Roberto Bianco, and Luigi Formisano. Role of fgfr3 in bladder cancer: Treatment landscape and future challenges. Cancer Treatment Reviews, 115:102530, 2023.

# **NeurIPS Paper Checklist**

#### 1. Claims

Question: Do the main claims made in the abstract and introduction accurately reflect the paper's contributions and scope?

Answer: [Yes]

Justification: The paper is focused on task adaptation of pathology foundation model on a single gpu for clinical applications. This is reflected accurately in the abstract and throughout the paper.

## Guidelines:

- The answer NA means that the abstract and introduction do not include the claims made in the paper.
- The abstract and/or introduction should clearly state the claims made, including the contributions made in the paper and important assumptions and limitations. A No or NA answer to this question will not be perceived well by the reviewers.
- The claims made should match theoretical and experimental results, and reflect how much the results can be expected to generalize to other settings.
- It is fine to include aspirational goals as motivation as long as it is clear that these goals
  are not attained by the paper.

## 2. Limitations

Question: Does the paper discuss the limitations of the work performed by the authors?

Answer: [Yes]

Justification: The authors have stated in conclusion how the proposed approach can be extended beyond the analysis presented in this study.

#### Guidelines:

- The answer NA means that the paper has no limitation while the answer No means that the paper has limitations, but those are not discussed in the paper.
- The authors are encouraged to create a separate "Limitations" section in their paper.
- The paper should point out any strong assumptions and how robust the results are to violations of these assumptions (e.g., independence assumptions, noiseless settings, model well-specification, asymptotic approximations only holding locally). The authors should reflect on how these assumptions might be violated in practice and what the implications would be.
- The authors should reflect on the scope of the claims made, e.g., if the approach was only tested on a few datasets or with a few runs. In general, empirical results often depend on implicit assumptions, which should be articulated.
- The authors should reflect on the factors that influence the performance of the approach. For example, a facial recognition algorithm may perform poorly when image resolution is low or images are taken in low lighting. Or a speech-to-text system might not be used reliably to provide closed captions for online lectures because it fails to handle technical jargon.
- The authors should discuss the computational efficiency of the proposed algorithms and how they scale with dataset size.
- If applicable, the authors should discuss possible limitations of their approach to address problems of privacy and fairness.
- While the authors might fear that complete honesty about limitations might be used by reviewers as grounds for rejection, a worse outcome might be that reviewers discover limitations that aren't acknowledged in the paper. The authors should use their best judgment and recognize that individual actions in favor of transparency play an important role in developing norms that preserve the integrity of the community. Reviewers will be specifically instructed to not penalize honesty concerning limitations.

## 3. Theory assumptions and proofs

Question: For each theoretical result, does the paper provide the full set of assumptions and a complete (and correct) proof?

Answer: [Yes]

Justification: All theorems and properties of the proposed method are provide in the main text and appendix with proofs.

#### Guidelines:

• The answer NA means that the paper does not include theoretical results.

- All the theorems, formulas, and proofs in the paper should be numbered and crossreferenced.
- All assumptions should be clearly stated or referenced in the statement of any theorems.
- The proofs can either appear in the main paper or the supplemental material, but if they appear in the supplemental material, the authors are encouraged to provide a short proof sketch to provide intuition.
- Inversely, any informal proof provided in the core of the paper should be complemented by formal proofs provided in appendix or supplemental material.
- Theorems and Lemmas that the proof relies upon should be properly referenced.

## 4. Experimental result reproducibility

Question: Does the paper fully disclose all the information needed to reproduce the main experimental results of the paper to the extent that it affects the main claims and/or conclusions of the paper (regardless of whether the code and data are provided or not)?

Answer: [Yes]

Justification: All method details, (hyper-)parameter settings, and other details (such as data) are included in the paper.

#### Guidelines:

- The answer NA means that the paper does not include experiments.
- If the paper includes experiments, a No answer to this question will not be perceived well by the reviewers: Making the paper reproducible is important, regardless of whether the code and data are provided or not.
- If the contribution is a dataset and/or model, the authors should describe the steps taken to make their results reproducible or verifiable.
- Depending on the contribution, reproducibility can be accomplished in various ways. For example, if the contribution is a novel architecture, describing the architecture fully might suffice, or if the contribution is a specific model and empirical evaluation, it may be necessary to either make it possible for others to replicate the model with the same dataset, or provide access to the model. In general, releasing code and data is often one good way to accomplish this, but reproducibility can also be provided via detailed instructions for how to replicate the results, access to a hosted model (e.g., in the case of a large language model), releasing of a model checkpoint, or other means that are appropriate to the research performed.
- While NeurIPS does not require releasing code, the conference does require all submissions to provide some reasonable avenue for reproducibility, which may depend on the nature of the contribution. For example
- (a) If the contribution is primarily a new algorithm, the paper should make it clear how to reproduce that algorithm.
- (b) If the contribution is primarily a new model architecture, the paper should describe the architecture clearly and fully.
- (c) If the contribution is a new model (e.g., a large language model), then there should either be a way to access this model for reproducing the results or a way to reproduce the model (e.g., with an open-source dataset or instructions for how to construct the dataset).
- (d) We recognize that reproducibility may be tricky in some cases, in which case authors are welcome to describe the particular way they provide for reproducibility. In the case of closed-source models, it may be that access to the model is limited in some way (e.g., to registered users), but it should be possible for other researchers to have some path to reproducing or verifying the results.

#### 5. Open access to data and code

Question: Does the paper provide open access to the data and code, with sufficient instructions to faithfully reproduce the main experimental results, as described in supplemental material?

Answer: [Yes]

Justification: The authors provide a link to code repository that contains implementation of the algorithm. Although the institutional data can not be released with the paper, the TCGA data that is used for external validation in the paper is publicly available.

## Guidelines:

- The answer NA means that paper does not include experiments requiring code.
- Please see the NeurIPS code and data submission guidelines (https://nips.cc/ public/guides/CodeSubmissionPolicy) for more details.
- While we encourage the release of code and data, we understand that this might not be possible, so "No" is an acceptable answer. Papers cannot be rejected simply for not including code, unless this is central to the contribution (e.g., for a new open-source benchmark).
- The instructions should contain the exact command and environment needed to run to reproduce the results. See the NeurIPS code and data submission guidelines (https: //nips.cc/public/guides/CodeSubmissionPolicy) for more details.
- The authors should provide instructions on data access and preparation, including how to access the raw data, preprocessed data, intermediate data, and generated data, etc.
- The authors should provide scripts to reproduce all experimental results for the new proposed method and baselines. If only a subset of experiments are reproducible, they should state which ones are omitted from the script and why.
- At submission time, to preserve anonymity, the authors should release anonymized versions (if applicable).
- Providing as much information as possible in supplemental material (appended to the paper) is recommended, but including URLs to data and code is permitted.

## 6. Experimental setting/details

Question: Does the paper specify all the training and test details (e.g., data splits, hyperparameters, how they were chosen, type of optimizer, etc.) necessary to understand the results?

Answer: [Yes]

Justification: All method details, (hyper-)parameter settings, and other details (such as data) are included in the paper.

#### Guidelines:

- The answer NA means that the paper does not include experiments.
- The experimental setting should be presented in the core of the paper to a level of detail that is necessary to appreciate the results and make sense of them.
- The full details can be provided either with the code, in appendix, or as supplemental material.

#### 7. Experiment statistical significance

Question: Does the paper report error bars suitably and correctly defined or other appropriate information about the statistical significance of the experiments?

Answer: [No]

Justification: The proposed method is rigorously evaluated on both internal and external testing datasets maintaining patient separation from the training and checkpoint selection (validation) datasets. For creating error bars, we need to train and evaluate the proposed method on multiple sets of training, validation, and testing splits obtained from institutional data, which is a computationally demanding task.

- The answer NA means that the paper does not include experiments.
- The authors should answer "Yes" if the results are accompanied by error bars, confidence intervals, or statistical significance tests, at least for the experiments that support the main claims of the paper.
- The factors of variability that the error bars are capturing should be clearly stated (for example, train/test split, initialization, random drawing of some parameter, or overall run with given experimental conditions).

- The method for calculating the error bars should be explained (closed form formula, call to a library function, bootstrap, etc.)
- The assumptions made should be given (e.g., Normally distributed errors).
- It should be clear whether the error bar is the standard deviation or the standard error of the mean.
- It is OK to report 1-sigma error bars, but one should state it. The authors should preferably report a 2-sigma error bar than state that they have a 96% CI, if the hypothesis of Normality of errors is not verified.
- For asymmetric distributions, the authors should be careful not to show in tables or figures symmetric error bars that would yield results that are out of range (e.g. negative error rates).
- If error bars are reported in tables or plots, The authors should explain in the text how they were calculated and reference the corresponding figures or tables in the text.

#### 8. Experiments compute resources

Question: For each experiment, does the paper provide sufficient information on the computer resources (type of compute workers, memory, time of execution) needed to reproduce the experiments?

Answer: [Yes]

Justification: It is mentioned that the authors used a single NVIDIA H100 GPU for experiments reported in this paper.

## Guidelines:

- The answer NA means that the paper does not include experiments.
- The paper should indicate the type of compute workers CPU or GPU, internal cluster, or cloud provider, including relevant memory and storage.
- The paper should provide the amount of compute required for each of the individual experimental runs as well as estimate the total compute.
- The paper should disclose whether the full research project required more compute than the experiments reported in the paper (e.g., preliminary or failed experiments that didn't make it into the paper).

## 9. Code of ethics

Question: Does the research conducted in the paper conform, in every respect, with the NeurIPS Code of Ethics https://neurips.cc/public/EthicsGuidelines?

Answer: [Yes]

Justification: This paper adheres to every aspect of the NeurIPS code of ethics, specifically using de-identified institutional and TCGA data for experiments.

## Guidelines:

- The answer NA means that the authors have not reviewed the NeurIPS Code of Ethics.
- If the authors answer No, they should explain the special circumstances that require a
  deviation from the Code of Ethics.
- The authors should make sure to preserve anonymity (e.g., if there is a special consideration due to laws or regulations in their jurisdiction).

#### 10. Broader impacts

Question: Does the paper discuss both potential positive societal impacts and negative societal impacts of the work performed?

Answer: [Yes]

Justification: The paper includes a section on clinical implications of the proposed method to highlight how this work can potentially impact cancer patients.

- The answer NA means that there is no societal impact of the work performed.
- If the authors answer NA or No, they should explain why their work has no societal impact or why the paper does not address societal impact.

- Examples of negative societal impacts include potential malicious or unintended uses (e.g., disinformation, generating fake profiles, surveillance), fairness considerations (e.g., deployment of technologies that could make decisions that unfairly impact specific groups), privacy considerations, and security considerations.
- The conference expects that many papers will be foundational research and not tied to particular applications, let alone deployments. However, if there is a direct path to any negative applications, the authors should point it out. For example, it is legitimate to point out that an improvement in the quality of generative models could be used to generate deepfakes for disinformation. On the other hand, it is not needed to point out that a generic algorithm for optimizing neural networks could enable people to train models that generate Deepfakes faster.
- The authors should consider possible harms that could arise when the technology is being used as intended and functioning correctly, harms that could arise when the technology is being used as intended but gives incorrect results, and harms following from (intentional or unintentional) misuse of the technology.
- If there are negative societal impacts, the authors could also discuss possible mitigation strategies (e.g., gated release of models, providing defenses in addition to attacks, mechanisms for monitoring misuse, mechanisms to monitor how a system learns from feedback over time, improving the efficiency and accessibility of ML).

#### 11. Safeguards

Question: Does the paper describe safeguards that have been put in place for responsible release of data or models that have a high risk for misuse (e.g., pretrained language models, image generators, or scraped datasets)?

Answer: [NA]

Justification: The paper uses private institute data and public TCGA data in the experiments.

#### Guidelines:

- The answer NA means that the paper poses no such risks.
- Released models that have a high risk for misuse or dual-use should be released with necessary safeguards to allow for controlled use of the model, for example by requiring that users adhere to usage guidelines or restrictions to access the model or implementing safety filters.
- Datasets that have been scraped from the Internet could pose safety risks. The authors should describe how they avoided releasing unsafe images.
- We recognize that providing effective safeguards is challenging, and many papers do
  not require this, but we encourage authors to take this into account and make a best
  faith effort.

## 12. Licenses for existing assets

Question: Are the creators or original owners of assets (e.g., code, data, models), used in the paper, properly credited and are the license and terms of use explicitly mentioned and properly respected?

Answer: [Yes]

Justification: Appropriate credits are provided to original publications (such as for TCGA datasets), wherever required.

- The answer NA means that the paper does not use existing assets.
- The authors should cite the original paper that produced the code package or dataset.
- The authors should state which version of the asset is used and, if possible, include a URL.
- The name of the license (e.g., CC-BY 4.0) should be included for each asset.
- For scraped data from a particular source (e.g., website), the copyright and terms of service of that source should be provided.

- If assets are released, the license, copyright information, and terms of use in the package should be provided. For popular datasets, paperswithcode.com/datasets has curated licenses for some datasets. Their licensing guide can help determine the license of a dataset.
- For existing datasets that are re-packaged, both the original license and the license of the derived asset (if it has changed) should be provided.
- If this information is not available online, the authors are encouraged to reach out to the asset's creators.

#### 13. New assets

Question: Are new assets introduced in the paper well documented and is the documentation provided alongside the assets?

Answer: [Yes]

Justification: The code to implement the proposed method is provided in an anonymized repository with appropriate license.

## Guidelines:

- The answer NA means that the paper does not release new assets.
- Researchers should communicate the details of the dataset/code/model as part of their submissions via structured templates. This includes details about training, license, limitations, etc.
- The paper should discuss whether and how consent was obtained from people whose asset is used.
- At submission time, remember to anonymize your assets (if applicable). You can either create an anonymized URL or include an anonymized zip file.

# 14. Crowdsourcing and research with human subjects

Question: For crowdsourcing experiments and research with human subjects, does the paper include the full text of instructions given to participants and screenshots, if applicable, as well as details about compensation (if any)?

Answer: [NA]

Justification: No human subjects are directly involved in this work.

#### Guidelines:

- The answer NA means that the paper does not involve crowdsourcing nor research with human subjects.
- Including this information in the supplemental material is fine, but if the main contribution of the paper involves human subjects, then as much detail as possible should be included in the main paper.
- According to the NeurIPS Code of Ethics, workers involved in data collection, curation, or other labor should be paid at least the minimum wage in the country of the data collector.

# 15. Institutional review board (IRB) approvals or equivalent for research with human subjects

Question: Does the paper describe potential risks incurred by study participants, whether such risks were disclosed to the subjects, and whether Institutional Review Board (IRB) approvals (or an equivalent approval/review based on the requirements of your country or institution) were obtained?

Answer: [NA]

Justification: No human subjects are directly involved in this work. However, appropriate approval for working with deidentified healthcare data from the institutional review board was obtained for this study.

#### Guidelines:

• The answer NA means that the paper does not involve crowdsourcing nor research with human subjects.

- Depending on the country in which research is conducted, IRB approval (or equivalent) may be required for any human subjects research. If you obtained IRB approval, you should clearly state this in the paper.
- We recognize that the procedures for this may vary significantly between institutions and locations, and we expect authors to adhere to the NeurIPS Code of Ethics and the guidelines for their institution.
- For initial submissions, do not include any information that would break anonymity (if applicable), such as the institution conducting the review.

#### 16. Declaration of LLM usage

Question: Does the paper describe the usage of LLMs if it is an important, original, or non-standard component of the core methods in this research? Note that if the LLM is used only for writing, editing, or formatting purposes and does not impact the core methodology, scientific rigorousness, or originality of the research, declaration is not required.

Answer: [No]

Justification: LLMs are not the core components of the proposed method.

- The answer NA means that the core method development in this research does not involve LLMs as any important, original, or non-standard components.
- Please refer to our LLM policy (https://neurips.cc/Conferences/2025/LLM) for what should or should not be described.

# **A Theoretical Analysis Details**

#### A.1 Permutation Invariance

A crucial property for MIL models is permutation invariance, which ensures that the order of instances in a bag does not affect the final prediction and below it is shown that the proposed TAPFM methods hold the permutation invariance property.

**Theorem 1** (Permutation Invariance). Let  $X = \{x_1, x_2, ..., x_K\}$  be a bag of instances and  $\pi$  be a permutation of indices  $\{1, 2, ..., K\}$ . The bag representation Z computed by TAPFM is invariant to permutation, i.e.,  $Z(X) = Z(\{x_{\pi(1)}, x_{\pi(2)}, ..., x_{\pi(K)}\})$ .

*Proof.* Let  $X=\{x_1,x_2,...,x_K\}$  be a bag of instances and  $\pi$  be a permutation of indices  $\{1,2,...,K\}$ . Let  $X_\pi=\{x_{\pi(1)},x_{\pi(2)},...,x_{\pi(K)}\}$  be the permuted bag.

Using matrix notation, let  $\mathbf{Z} = [z_1^T, z_2^T, \dots, z_K^T]^T \in \mathbb{R}^{K \times D}$  be the feature matrix and  $\mathbf{a} = [a_1, a_2, \dots, a_K]^T \in \mathbb{R}^K$  be the attention weight vector for the original ordering.

Let  $\mathbf{P}_{\pi} \in \mathbb{R}^{K \times K}$  be the permutation matrix corresponding to  $\pi$ . Then, the feature matrix and attention vector for the permuted bag can be written as:

$$\mathbf{Z}_{\pi} = \mathbf{P}_{\pi} \mathbf{Z} \tag{16}$$

$$\mathbf{a}_{\pi} = \mathbf{P}_{\pi} \mathbf{a} \tag{17}$$

The bag representation for the original ordering is:

$$Z(X) = \mathbf{Z}^T \mathbf{a} = \sum_{i=1}^K a_i z_i$$
(18)

The bag representation for the permuted ordering is:

$$Z(X_{\pi}) = \mathbf{Z}_{\pi}^{T} \mathbf{a}_{\pi} \tag{19}$$

$$= (\mathbf{P}_{\pi} \mathbf{Z})^T (\mathbf{P}_{\pi} \mathbf{a}) \tag{20}$$

$$=\mathbf{Z}^T\mathbf{P}_{\pi}^T\mathbf{P}_{\pi}\mathbf{a} \tag{21}$$

$$= \mathbf{Z}^T \mathbf{a} \tag{22}$$

$$= Z(X) \tag{23}$$

The equality  $\mathbf{P}_{\pi}^T \mathbf{P}_{\pi} = \mathbf{I}$  holds because permutation matrices are orthogonal. Therefore,  $Z(X) = Z(X_{\pi})$ , which proves that the bag representation is permutation invariant.

In component form, this is equivalent to:

$$Z(X_{\pi}) = \sum_{i=1}^{K} a_{\pi(i)} z_{\pi(i)} = \sum_{j=1}^{K} a_{j} z_{j} = Z(X)$$
(24)

where the change of variables  $j = \pi^{-1}(i)$  is used.

## A.2 Computational Complexity

**Theorem 2** (Computational Complexity). The computational complexity of TAPFM for processing a single bag of K instances is  $\mathcal{O}(K \cdot C_{ViT})$ , where  $C_{ViT}$  is the complexity of a forward and backward pass through the specific ViT of a PFM for a single instance.

*Proof.* The computational complexity of TAPFM is analyzed by examining each step of the proposed Algorithm 1 in detail:

## • Feature Extraction (Forward Pass):

Each of the K tiles in the bag is passed through the ViT model to extract features. The complexity of processing a single tile depends on the ViT architecture:

- Patch embedding:  $\mathcal{O}(P^2 \cdot C \cdot D)$ , where P is the patch size, C is the number of channels, and D is the embedding dimension. - Self-attention layers:  $\mathcal{O}(L \cdot N^2 \cdot D)$ , where L is the number of layers, N is the number of tokens (patches). - MLP blocks:  $\mathcal{O}(L \cdot N \cdot D^2)$ .

The total complexity for a single tile forward pass is  $\mathcal{O}(C_{\text{ViT\_forward}}) = \mathcal{O}(P^2 \cdot C \cdot D + L \cdot N^2 \cdot D + L \cdot N \cdot D^2)$ .

For K tiles, the total forward pass complexity is  $\mathcal{O}(K \cdot C_{\text{ViT forward}})$ .

## • Attention Weight Computation:

For each tile i, the average attention weight is computed by aggregating over H attention heads and N tokens:

$$a_i = \frac{1}{H} \sum_{h=1}^{H} \frac{1}{N} \sum_{j=1}^{N} A_{cls,j}^h$$
 (25)

This requires  $\mathcal{O}(H \cdot N)$  operations per tile, resulting in a total complexity of  $\mathcal{O}(K \cdot H \cdot N)$  for all tiles.

## • Bag Representation Computation:

Computing the weighted sum of feature vectors:

$$Z = \mathbf{Z}^T \mathbf{a} = \sum_{i=1}^K a_i z_i \tag{26}$$

This requires  $\mathcal{O}(K \cdot D)$  operations, where D is the feature dimension.

#### · Aggregator Forward and Backward Pass:

The aggregator applies a linear transformation followed by a sigmoid activation:

$$\hat{y} = \sigma(WZ + b) \tag{27}$$

The forward pass has complexity  $\mathcal{O}(D)$  for the matrix-vector multiplication.

Computing the aggregator loss and its gradient with respect to the bag representation has complexity  $\mathcal{O}(D)$ .

Updating the aggregator parameters has complexity  $\mathcal{O}(D)$ .

## • Computing Gradients for the PFM:

The feature loss is:

$$\mathcal{L}_{feature} = -\text{tr}(\mathbf{Z}\mathbf{G}_z^T) = \sum_{i=1}^K \langle z_i, g_{z_i} \rangle$$
 (28)

Computing this loss has complexity  $\mathcal{O}(K \cdot D)$ .

The attention loss is:

$$\mathcal{L}_{attention} = \mathbf{a}^T \mathbf{g}_a = \sum_{i=1}^K a_i \cdot g_{a_i}$$
 (29)

Computing this loss has complexity  $\mathcal{O}(K)$ .

#### PFM Backward Pass:

The backward pass through the ViT for all K tiles has a complexity of  $\mathcal{O}(K \cdot C_{\text{ViT\_backward}})$ , which is typically on the same order as the forward pass:  $\mathcal{O}(C_{\text{ViT\_backward}}) = \mathcal{O}(P^2 \cdot C \cdot D + L \cdot N^2 \cdot D + L \cdot N \cdot D^2)$ .

Combining all steps, the total computational complexity is:

$$\mathcal{O}(K \cdot C_{\text{ViT forward}} + K \cdot H \cdot N + K \cdot D + D + K \cdot D + K + K \cdot C_{\text{ViT backward}}) \tag{30}$$

Since  $C_{\text{ViT}} = C_{\text{ViT\_forward}} + C_{\text{ViT\_backward}}$  and typically  $C_{\text{ViT}} \gg H \cdot N$  and  $C_{\text{ViT}} \gg D$ , the overall complexity is dominated by the ViT forward and backward passes, resulting in  $\mathcal{O}(K \cdot C_{\text{ViT}})$ .

This complexity analysis shows that the proposed TAPFM approach scales linearly with the number of instances in the bag. The constant factor  $C_{\text{ViT}}$  depends on the specific architecture of the Vision Transformer but is independent of the bag size.

#### A.3 Space Complexity Analysis

In addition to time complexity, space complexity is a critical consideration for practical deployment of TAPFM, especially for gigapixel WSIs processed using transformer-based models.

**Theorem 3** (Space Complexity). The space complexity of TAPFM for processing a single bag of K instances (tiles) is  $\mathcal{O}(|\theta_{PFM}| + K \cdot (S_{act} + S_{grad}))$ , where  $|\theta_{PFM}|$  is the size of the PFM parameters, and  $S_{act}$  and  $S_{grad}$  are the memory requirements for activations and gradients per instance, respectively.

*Proof.* The space complexity of TAPFM is analyzed by examining the memory requirements of each component in the proposed approach as follows:

- Model Parameter Storage: The memory required to store the ViT parameters is  $\mathcal{O}(|\theta_{PFM}|)$ , which can be further decomposed as  $\mathcal{O}(L \cdot N \cdot D^2)$ , where L is the number of transformer layers, N is the number of tokens, and D is the embedding dimension.
- Feature Matrix Storage: For a bag of K instances, the feature matrix  $\mathbf{Z} \in \mathbb{R}^{K \times D}$  requires  $\mathcal{O}(K \cdot D)$  memory.
- Attention Vector Storage: The attention weight vector  $\mathbf{a} \in \mathbb{R}^K$  requires  $\mathcal{O}(K)$  memory.
- Activation Memory: During the forward pass, each instance requires storing intermediate activations for all transformer layers. For a single instance, this requires  $\mathcal{O}(L \cdot N \cdot D)$  memory for hidden states and  $\mathcal{O}(L \cdot H \cdot N^2)$  for attention maps, where H is the number of attention heads. Let's denote the total activation memory per instance as  $S_{act} = \mathcal{O}(L \cdot N \cdot D + L \cdot H \cdot N^2)$ .
- Gradient Memory: During backpropagation, gradients for both activations and parameters must be stored. The memory requirement for gradients per instance is denoted as  $S_{grad}$ , which is typically on the same order as  $S_{act}$ .
- Aggregator Memory: The aggregator requires  $\mathcal{O}(D)$  memory for parameters and  $\mathcal{O}(1)$  for the output, which is negligible compared to the PFM memory requirements.
- Gradient Matrices for Feature and Attention: The feature gradient matrix  $\mathbf{G}_z \in \mathbb{R}^{K \times D}$  requires  $\mathcal{O}(K \cdot D)$  memory, and the attention gradient vector  $\mathbf{g}_a \in \mathbb{R}^K$  requires  $\mathcal{O}(K)$  memory.

Combining all components and identifying the dominant terms, the total space complexity is:

$$\mathcal{O}(|\theta_{PFM}| + K \cdot D + K + K \cdot S_{act} + K \cdot S_{grad} + K \cdot D + K) \tag{31}$$

Since  $S_{act}$  and  $S_{qrad}$  are typically much larger than D, and combining like terms produces:

$$\mathcal{O}(|\theta_{PFM}| + K \cdot (S_{act} + S_{grad})) \tag{32}$$

Above equation indicates that the memory requirements of TAPFM scale linearly with the number of instances (tiles) K. However, the constant factors  $S_{act}$  and  $S_{grad}$  can be substantial for large ViT models, potentially limiting the number of instances that can be processed simultaneously on a single GPU.

#### A.4 Task-Specific Adaptation without Catastrophic Forgetting

**Proposition 2** (Preservation of Pretrained Knowledge). The proposed TAPFM approach effectively implements a specialized form of continual learning that prevents catastrophic forgetting. The Fisher information matrix for pretrained parameters is implicitly preserved:

$$F_{\theta_{PFM}} = \mathbb{E}_{p(x,y)} \left[ \nabla_{\theta_{PFM}} \log p(z|x;\theta_{PFM}) \nabla_{\theta_{PFM}} \log p(z|x;\theta_{PFM})^T \right]$$
(33)

*Proof.* Catastrophic forgetting occurs when fine-tuning a pre-trained model on a new task destroys the knowledge acquired during pretraining. In information-theoretic terms, this happens when parameter updates move away from regions of high Fisher information with respect to the pretraining task.

The Fisher information matrix  $F_{\theta_{PFM}}$  characterizes the curvature of the loss landscape around the pretrained parameters. It quantifies how sensitive the model's output is to small changes in each parameter. Parameters with high Fisher information are crucial for the model's performance on the pretraining task.

In standard fine-tuning, the gradient update is:

$$\Delta \theta_{PFM} = -\eta \nabla_{\theta_{PFM}} \mathcal{L}_{task} \tag{34}$$

This update does not account for the importance of parameters for the pretraining task, potentially leading to catastrophic forgetting. In contrast, optimal updates for preserving pretrained knowledge while adapting to a new task would be of the form:

$$\Delta \theta_{PFM} = -\eta F_{\theta_{PFM}}^{-1} \nabla_{\theta_{PFM}} \mathcal{L}_{task} \tag{35}$$

This is a form of natural gradient descent, which adapts the update direction based on the curvature of the loss landscape.

The proposed TAPFM approach implicitly approximates this behavior through gradient detachment. By separating the aggregator and PFM optimization, TAPFM allows the PFM to adapt more conservatively. The detached gradients from the aggregator act as a filtered signal that guides the PFM to adapt while respecting its pretrained structure.

Specifically, the proposed PFM update is:

$$\Delta \theta_{PFM} = -\eta \nabla_{\theta_{PFM}} \mathcal{L}_{PFM} \tag{36}$$

where  $\mathcal{L}_{PFM}$  is defined using detached gradients from the aggregator. This approach resembles a regularized optimization problem:

$$\min_{\theta_{PFM}} \mathcal{L}_{task}(\theta_{PFM}) + \lambda \cdot \mathcal{R}(\theta_{PFM} - \theta_{PFM}^{pretrained})$$
 (37)

where  $\mathcal{R}$  is an implicit regularization term that penalizes deviations from the pretrained parameters. The solution to this regularized problem can be approximated as:

$$\Delta \theta_{PFM} \approx -\eta (I + \lambda \cdot F_{\theta_{PFM}})^{-1} \nabla_{\theta_{PFM}} \mathcal{L}_{task}$$
 (38)

As  $\lambda$  increases, this approaches the natural gradient update:

$$\Delta\theta_{PFM} \approx -\eta \lambda^{-1} F_{\theta_{PFM}}^{-1} \nabla_{\theta_{PFM}} \mathcal{L}_{task} \approx -\eta' F_{\theta_{PFM}}^{-1} \nabla_{\theta_{PFM}} \mathcal{L}_{task}$$
 (39)

where  $\eta' = \eta \lambda^{-1}$  is an effective learning rate.

The detached gradient approach of TAPFM serves as an implicit regularization mechanism that enables task-specific adaptation while preserving the foundational knowledge embedded in the pretrained model. This balance between adaptation and preservation is especially important for PFMs, where pretraining captures general tissue morphology and fine-tuning adapts to specific clinically relevant tasks.

#### A.5 Cosine Regularization for Feature Alignment Loss

The feature alignment loss in equation 5 encourages feature vectors to move in the direction that reduces the classification loss. However, in certain scenarios, direct optimization of this loss may lead to updates where feature vectors and gradients point in opposing directions, potentially causing unstable training dynamics. To mitigate this issue, a cosine regularization term is considered. The cosine regularization term is defined as:  $\mathcal{L}_{reg} = \sum_{i=1}^K (1 - \cos(z_i, g_{z_i}))$  where  $\cos(z_i, g_{z_i})$  represents the cosine similarity between the feature vector  $z_i$  and its gradient  $g_{z_i}$ , calculated as:


$$\cos(z_i, g_{z_i}) = \frac{\langle z_i, g_{z_i} \rangle}{\|z_i\|_2 \cdot \|g_{z_i}\|_2} \tag{40}$$

This regularization term penalizes scenarios where feature vectors and their gradients are oriented in opposite directions (negative cosine similarity). When incorporated into the task adaptation loss, the complete objective becomes:


$$\mathcal{L}_{PFM} = \mathcal{L}_{feature} + \lambda \mathcal{L}_{attention} + \beta \mathcal{L}_{reg}$$
 (41)

where  $\beta$  is a hyperparameter controlling the strength of the regularization. The purpose of this regularization is to promote more stable optimization by encouraging gradual updates to the learned representations while still allowing adaptation to the downstream task. Theoretically, this prevents drastic changes in feature space that might compromise the pretrained knowledge while ensuring that updates remain aligned with the classification objective.

# **B** Training Loss Curves



(a) Training loss variation with respect to lambda in TAL (equation 7) for H-Optimus-0 (TAPFM) model.





(b) Training loss variation with the number of tiles for H-Optimus-0 (TAPFM) model.

Figure 4: Ablations studies for *FGFR3* prediction in BLCA patients.

## C TAPFM Optimization Stability

Figure 5 empirically demonstrates the stabilization benefit of TAPFM's detached gradient approach compared to unified computational graph training. When attempting joint optimization with a unified graph (left panel), the training loss exhibits unstable oscillations around 0.85 without convergence over 20 epochs, indicating optimization conflicts between the PFM and aggregator parameters. In contrast, TAPFM's detached gradient approach (right panel) shows smooth exponential decay from 0.89 to below 0.08, confirming the theoretical analysis in Section 3.4. This stable convergence enables effective single-GPU training where joint optimization fails due to competing gradient signals through shared parameters.





- (a) Unified computational graph (unstable)
- (b) TAPFM detached gradients (stable)

Figure 5: Training loss comparison demonstrating optimization stability. Unified computational graph training fails to converge due to gradient conflicts, while TAPFM's detached approach enables smooth convergence.

## **D** Additional Results

## **D.1** Mutation Prediction

To provide a comprehensive assessment accounting for class imbalance, we report Area Under the Precision-Recall Curve (AUPRC) values for the mutation prediction experiments. Tables 3 and 4 present AUPRC results for the binary and multi-label mutation prediction tasks, respectively.

## **D.2** Survival Prediction

To demonstrate TAPFM's versatility beyond mutation prediction, we evaluated its performance on overall survival prediction using TCGA-BLCA and TCGA-LUAD cohorts. For this task, we replaced the classification head with a multi-task logistic regression (MTLR) layer and used partial log-likelihood loss for optimization [37]. Results in Table 5 demonstrate that TAPFM's task adaptation approach extends effectively to time-to-event prediction tasks as well.

Table 3: Performance comparison of different PFM and MIL aggregation methods for binary classification tasks in terms of AUPRC (mean  $\pm$  95% CI from 5-fold cross-validation). N indicates the number of patients in the testing cohort. Best and second best models are in bold and underlined text, respectively.

Model	BLCA	FGFR3	LUAD EGFR		
	Institutional (N = 194)	TCGA $(N = 260)$	Institutional (N = 876)	TCGA $(N = 438)$	
Fixed-PFM with Trained MIL	Aggregators				
UNI + DSMIL	$0.4523 \pm 0.047$	$0.4687 \pm 0.048$	$0.4785 \pm 0.038$	$0.5142 \pm 0.04$	
UNI + CLAM	$0.4571 \pm 0.046$	$0.4712 \pm 0.047$	$0.4831 \pm 0.037$	$0.5189 \pm 0.04$	
UNI + VarMIL	$0.4618 \pm 0.045$	$0.4763 \pm 0.046$	$0.4893 \pm 0.036$	$0.5247 \pm 0.04$	
UNI + ABMIL	$0.4597 \pm 0.046$	$0.4789 \pm 0.046$	$0.4862 \pm 0.037$	$0.5312 \pm 0.03$	
GigaPath + DSMIL	$0.5634 \pm 0.041$	$0.6247 \pm 0.039$	$0.5473 \pm 0.034$	$0.6189 \pm 0.03$	
GigaPath + CLAM	$0.5683 \pm 0.040$	$0.6294 \pm 0.038$	$0.5521 \pm 0.033$	$0.6235 \pm 0.03$	
GigaPath + VarMIL	$0.5741 \pm 0.039$	$0.6352 \pm 0.037$	$0.5584 \pm 0.032$	$0.6298 \pm 0.03$	
GigaPath + ABMIL	$0.5789 \pm 0.039$	$0.6397 \pm 0.036$	$0.5627 \pm 0.032$	$0.6341 \pm 0.03$	
H-Optimus-0 + DSMIL	$0.5891 \pm 0.038$	$0.6453 \pm 0.036$	$0.5692 \pm 0.031$	$0.6429 \pm 0.03$	
H-Optimus-0 + CLAM	$0.5924 \pm 0.038$	$0.6512 \pm 0.035$	$0.5748 \pm 0.030$	$0.6481 \pm 0.03$	
H-Optimus-0 + VarMIL	$0.5987 \pm 0.037$	$0.6583 \pm 0.034$	$0.5809 \pm 0.029$	$0.6547 \pm 0.03$	
H-Optimus-0 + ABMIL	$0.6023 \pm 0.037$	$0.6621 \pm 0.034$	$0.5841 \pm 0.029$	$0.6583 \pm 0.03$	
Fine-tuned (FT) PFM with MI	L Aggregators				
UNI + DSMIL (FT)	$0.5247 \pm 0.044$	$0.5389 \pm 0.045$	$0.5134 \pm 0.036$	$0.5497 \pm 0.04$	
UNI + CLAM (FT)	$0.5293 \pm 0.043$	$0.5427 \pm 0.044$	$0.5189 \pm 0.035$	$0.5558 \pm 0.03$	
UNI + VarMIL (FT)	$0.5361 \pm 0.042$	$0.5487 \pm 0.043$	$0.5258 \pm 0.034$	$0.5631 \pm 0.03$	
UNI + ABMIL (FT)	$0.5412 \pm 0.042$	$0.5463 \pm 0.044$	$0.5297 \pm 0.034$	$0.5689 \pm 0.03$	
GigaPath + DSMIL (FT)	$0.5923 \pm 0.039$	$0.6687 \pm 0.034$	$0.6142 \pm 0.031$	$0.6547 \pm 0.03$	
GigaPath + CLAM (FT)	$0.5971 \pm 0.038$	$0.6734 \pm 0.033$	$0.6213 \pm 0.030$	$0.6608 \pm 0.03$	
GigaPath + VarMIL (FT)	$0.6047 \pm 0.037$	$0.6812 \pm 0.032$	$0.6301 \pm 0.029$	$0.6689 \pm 0.03$	
GigaPath + ABMIL (FT)	$0.6021 \pm 0.038$	$0.6781 \pm 0.033$	$0.6358 \pm 0.029$	$0.6723 \pm 0.03$	
H-Optimus-0 + DSMIL (FT)	$0.6187 \pm 0.036$	$0.6794 \pm 0.033$	$0.6473 \pm 0.028$	$0.6831 \pm 0.03$	
H-Optimus-0 + CLAM (FT)	$0.6234 \pm 0.035$	$0.6847 \pm 0.032$	$0.6541 \pm 0.027$	$0.6912 \pm 0.03$	
H-Optimus-0 + VarMIL (FT)	$0.6318 \pm 0.034$	$0.6931 \pm 0.031$	$0.6624 \pm 0.026$	$0.6989 \pm 0.03$	
H-Optimus-0 + ABMIL (FT)	$0.6289 \pm 0.035$	$0.6897 \pm 0.032$	$0.6671 \pm 0.027$	$0.6958 \pm 0.03$	
Proposed TAPFM method					
UNI (TAPFM)	$0.6142 \pm 0.041$	$0.6389 \pm 0.039$	$0.6542 \pm 0.030$	$0.6647 \pm 0.03$	
Gigapath (TAPFM)	$0.7235 \pm 0.032$	$0.7251 \pm 0.028$	$0.7089 \pm 0.025$	$0.7143 \pm 0.02$	
H-Optimus-0 (TAPFM)	$0.7163 \pm 0.035$	$0.7164 \pm 0.024$	$0.7287 \pm 0.023$	$0.7319 \pm 0.01$	

Table 4: Performance comparison on multi-label classification of actionable mutations in LUAD in terms of AUPRC (mean  $\pm$  95% CI from 5-fold cross-validation). Based on binary classification results (Table 1), only the top performers are shown, as performance varied primarily by foundation model type.

Model	Institutional Cohort $(N=876)$				Macro Average	
1120402	EGFR	KRAS	MET	ALK	ivanero rayeringe	
UNI (TAPFM)	$0.6589 \pm 0.032$	$0.6047 \pm 0.036$	$0.1673 \pm 0.061$	$0.1429 \pm 0.068$	$0.3934 \pm 0.031$	
Gigapath (TAPFM)	$\textbf{0.6872} \pm \textbf{0.027}$	$\textbf{0.6396} \pm \textbf{0.031}$	$0.2483 \pm 0.055$	$0.1507 \pm 0.062$	$0.4315 \pm 0.026$	
H-Optimus-0 (TAPFM)	$0.6773 \pm 0.025$	$0.6177 \pm 0.029$	$\textbf{0.3457} \pm \textbf{0.051}$	$\textbf{0.1951} \pm \textbf{0.058}$	$\textbf{0.4590} \pm \textbf{0.024}$	
TCGA (N = 438)						
UNI (TAPFM)	$0.6631 \pm 0.038$	$0.6095 \pm 0.042$	$0.1547 \pm 0.072$	$0.1392 \pm 0.081$	$0.3916 \pm 0.036$	
GigaPath (TAPFM)	$0.6850 \pm 0.032$	$0.6413 \pm 0.036$	$0.2374 \pm 0.063$	$0.1431 \pm 0.074$	$0.4269 \pm 0.031$	
H-Optimus-0 (TAPFM)	$\textbf{0.6942} \pm \textbf{0.030}$	$0.6284 \pm 0.034$	$\textbf{0.3104} \pm \textbf{0.059}$	$\textbf{0.1862} \pm \textbf{0.069}$	$\textbf{0.4548} \pm \textbf{0.029}$	

Table 5: Overall survival prediction performance comparison on TCGA cohorts. Results are reported as concordance index (C-index) with 95% confidence intervals from 5-fold cross-validation. Higher values indicate better survival prediction.

method	TC	GA-BLCA	TCGA-LUAD		
me with the second seco	C-index	C-index 95% CI		95% CI	
UNI (TAPFM)	0.6218	(0.5759, 0.6677)	0.6687	(0.6042, 0.7332)	
GigaPath (TAPFM)	0.6341	(0.5935, 0.6747)	0.6825	(0.6214, 0.7436)	
H-Optimus-0 (TAPFM)	0.6408	(0.6045, 0.6771)	0.6953	(0.6371, 0.7535)	